-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Safety Production Series (7): Keyuan Pharmaceutical Holds the 2024 Fourth Quarter Safety Committee Work Summary Meeting!
Publish Time:
2025-01-05
The meeting began with a comprehensive review of the company’s safety production efforts for 2024. Over the past year, Keyuan Pharmaceutical has consistently adhered to the guiding principle of "Safety First, Prevention-Oriented, and Comprehensive Management." By strengthening safety management, refining safety protocols, and intensifying safety training, the company has effectively elevated its overall safety standards, successfully achieving its annual goals: "zero safety incidents, zero environmental pollution, and zero administrative penalties" for the entire year.
On January 3, Keyuan Pharmaceutical (stock code: 301281.SZ) held its Q4 2024 Safety Committee Work Summary Meeting, comprehensively reviewing the company's 2024 safety production efforts and precisely outlining the key priorities for 2025, thereby laying a solid foundation for the company's safe and stable growth. Senior company leaders, heads of various departments, and relevant members of the Safety Committee attended the meeting.
The meeting began with a comprehensive review of the company’s safety production efforts for 2024. Over the past year, Keyuan Pharmaceutical has consistently adhered to the guiding principle of "Safety First, Prevention-Oriented, and Comprehensive Management." By strengthening safety production management, refining safety protocols, and intensifying safety training, the company has effectively elevated its overall safety standards, successfully achieving its annual goals: "zero safety incidents, zero environmental pollution, and zero administrative penalties" for the entire year.
While summarizing the achievements, the meeting conducted an in-depth analysis on safety accident警示教育, case studies of typical "three violations" incidents, implementation of the red-line management model, and dissemination of relevant laws and regulations. The meeting emphasized that all departments must remain vigilant at all times, strengthen risk assessments and early warning systems, and ensure that potential safety hazards are promptly identified and addressed.
Regarding the 2025 work on safe production, the meeting put forward the following specific requirements:
Further strengthen the implementation of the safety production responsibility system.
Safe production: The alarm rings continuously.
All departments must sign safety production responsibility agreements at every level, clearly defining the safety responsibilities of managers and employees at all tiers, ensuring that safety responsibilities are assigned to specific individuals and fully implemented. At the same time, it is essential to strengthen safety production assessments and enhance the rigor of rewards and punishments—recognizing and rewarding departments and individuals who excel in safety performance, while holding those who fail to deliver accountable with serious consequences.
Strengthen safety training and education
Safe production: The alarm rings continuously.
The company will continue to organize various safety training activities to enhance employees' safety awareness and operational skills, especially among newly hired staff.
Strengthen daily safety inspections and hazard identification, assessment, and remediation.
Safe production: The alarm rings continuously.
All departments are required to conduct regular safety inspections and hazard assessments, promptly addressing and implementing corrections for any issues identified, ensuring that no blind spots or hidden risks remain.
Strengthen emergency management and incident response capabilities
Safe production: The alarm rings continuously.
The company will continue to refine its emergency response plans and procedures, strengthen emergency drills and training initiatives, and enhance employees' ability to respond effectively to emergencies and handle incidents.
Safe production is the lifeline of enterprise development—vigilance must never be relaxed, no matter the circumstances. All departments should strictly follow the meeting’s requirements to implement all safety measures and protocols, ensuring that the company’s safe production situation remains consistently stable and improves. Meanwhile, the meeting encouraged all employees to actively participate in safety initiatives, working together to contribute to Kexuan Pharmaceutical’s steady, high-quality growth.
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline